Ads
related to: ceftriaxone for mssa pneumonia infection prevention protocol- What is CAPVAXIVE?
Learn About CAPVAXIVE
Visit the Official Patient Site.
- Disease Information
Learn About the Risk
Visit Here for More Information.
- FAQs & More
Find Answers to Your Questions
Get More Information Here.
- Get CAPVAXIVE
Find a Pharmacy Near You
Access Resources Here.
- What is CAPVAXIVE?
Search results
Results From The WOW.Com Content Network
Staphylococcus aureus, a gram-positive bacterium, is the most common cause of nosocomial pneumonia and surgical site infections and the second-most common cause of bloodstream, cardiovascular, and eye, ear, nose, and throat infections. [65] S. aureus is by far the leading cause of skin and soft tissue HAIs, which can lead to potentially lethal ...
Ceftriaxone, sold under the brand name Rocephin, is a third-generation cephalosporin antibiotic used for the treatment of a number of bacterial infections. [4] These include middle ear infections, endocarditis, meningitis, pneumonia, bone and joint infections, intra-abdominal infections, skin infections, urinary tract infections, gonorrhea, and pelvic inflammatory disease. [4]
Ventilator-associated pneumonia (VAP) is a type of lung infection that occurs in people who are on mechanical ventilation breathing machines in hospitals. As such, VAP typically affects critically ill persons that are in an intensive care unit (ICU) and have been on a mechanical ventilator for at least 48 hours.
Vaccination with Hib conjugate vaccine is effective in preventing Hib infection but does not prevent infection with NTHi strains. [48] H. influenzae can cause respiratory tract infections including pneumonia, otitis media, epiglottitis (swelling in the throat), eye infections and bloodstream infection, meningitis. It can also cause cellulitis ...
[6] [5] [7] Ceftolozane is a cephalosporin antibiotic, developed for the treatment of infections with gram-negative bacteria that are resistant to conventional antibiotics. [8] It was studied for urinary tract infections, intra-abdominal infections and ventilator-associated bacterial pneumonia.
[7] [8] In 2009, ceftaroline had completed phase-III clinical trials for community-acquired pneumonia comparing it against ceftriaxone with non-inferior results and similar adverse reaction profile. [6] However, only results for phase-II clinical trials in treatment of complicated skin and skin structure infections have been published. [12]
Ads
related to: ceftriaxone for mssa pneumonia infection prevention protocol